Gai‐Xia Lu

854 total citations
25 papers, 496 citations indexed

About

Gai‐Xia Lu is a scholar working on Cancer Research, Molecular Biology and Oncology. According to data from OpenAlex, Gai‐Xia Lu has authored 25 papers receiving a total of 496 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Cancer Research, 14 papers in Molecular Biology and 6 papers in Oncology. Recurrent topics in Gai‐Xia Lu's work include MicroRNA in disease regulation (12 papers), Cancer-related molecular mechanisms research (10 papers) and Circular RNAs in diseases (8 papers). Gai‐Xia Lu is often cited by papers focused on MicroRNA in disease regulation (12 papers), Cancer-related molecular mechanisms research (10 papers) and Circular RNAs in diseases (8 papers). Gai‐Xia Lu collaborates with scholars based in China and Tanzania. Gai‐Xia Lu's co-authors include Yu‐Shui Ma, Da Fu, Zhongwei Lv, Xianling Cong, Zhengyan Chang, Fei Yu, Ruting Xie, Huiqiong Yang, Xiaoming Zhong and Shaobo Xue and has published in prestigious journals such as PLoS ONE, Molecular Cancer and Molecular Therapy.

In The Last Decade

Gai‐Xia Lu

24 papers receiving 495 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gai‐Xia Lu China 15 368 297 94 53 40 25 496
Shi-Xun Lu China 12 381 1.0× 286 1.0× 142 1.5× 74 1.4× 56 1.4× 12 572
Mariangela Balistreri Italy 10 270 0.7× 219 0.7× 124 1.3× 89 1.7× 26 0.7× 15 487
Yanmei Cui China 13 450 1.2× 333 1.1× 138 1.5× 77 1.5× 39 1.0× 16 641
Jue‐Yu Zhou China 15 426 1.2× 278 0.9× 110 1.2× 54 1.0× 41 1.0× 42 591
Zetian Shen China 13 214 0.6× 174 0.6× 109 1.2× 126 2.4× 41 1.0× 30 439
Ai‐Yan Xing China 11 373 1.0× 282 0.9× 80 0.9× 38 0.7× 17 0.4× 24 482
Shican Yan China 9 225 0.6× 181 0.6× 163 1.7× 79 1.5× 33 0.8× 11 434
Weimin Mao China 12 335 0.9× 272 0.9× 93 1.0× 126 2.4× 29 0.7× 28 558
Maria Apicella Italy 6 274 0.7× 191 0.6× 158 1.7× 83 1.6× 15 0.4× 6 446
Daniel Kerr United States 8 231 0.6× 204 0.7× 171 1.8× 44 0.8× 48 1.2× 16 439

Countries citing papers authored by Gai‐Xia Lu

Since Specialization
Citations

This map shows the geographic impact of Gai‐Xia Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gai‐Xia Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gai‐Xia Lu more than expected).

Fields of papers citing papers by Gai‐Xia Lu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gai‐Xia Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gai‐Xia Lu. The network helps show where Gai‐Xia Lu may publish in the future.

Co-authorship network of co-authors of Gai‐Xia Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Gai‐Xia Lu. A scholar is included among the top collaborators of Gai‐Xia Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gai‐Xia Lu. Gai‐Xia Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Wang, Congcong, Yutian Li, Guoqiang Wang, et al.. (2024). Prognostic factors in children and adolescents with differentiated thyroid cancer treated with total thyroidectomy and radioiodine therapy: a retrospective two-center study from China. Frontiers in Endocrinology. 15. 1419141–1419141. 2 indexed citations
3.
Wang, Congcong, Yutian Li, Guoqiang Wang, et al.. (2024). Prognostic value of pre-ablation stimulated thyroglobulin in children and adolescents with differentiated thyroid cancer. Future Oncology. 20(40). 3463–3470. 1 indexed citations
4.
5.
Wang, Congcong, Gai‐Xia Lu, Yutian Li, et al.. (2023). Long-term prognostic analysis of children and adolescents with differentiated thyroid carcinoma based on therapeutic response to initial radioiodine therapy. Frontiers in Endocrinology. 14. 1217092–1217092. 3 indexed citations
6.
7.
Ma, Yu‐Shui, Sun Feng, Lan Lin, et al.. (2021). Protein disulfide isomerase inhibits endoplasmic reticulum stress response and apoptosis via its oxidoreductase activity in colorectal cancer. Cellular Signalling. 86. 110076–110076. 8 indexed citations
8.
Yang, Xiao‐Li, Yu‐Shui Ma, Yushan Liu, et al.. (2021). microRNA-873 inhibits self-renewal and proliferation of pancreatic cancer stem cells through pleckstrin-2-dependent PI3K/AKT pathway. Cellular Signalling. 84. 110025–110025. 30 indexed citations
9.
Ma, Yu‐Shui, Xiao‐Li Yang, Yushan Liu, et al.. (2021). Long non-coding RNA NORAD promotes pancreatic cancer stem cell proliferation and self-renewal by blocking microRNA-202-5p-mediated ANP32E inhibition. Journal of Translational Medicine. 19(1). 400–400. 20 indexed citations
10.
Jia, Chengyou, Wei Xiang, Jibin Liu, et al.. (2021). MiR-9-1 Suppresses Cell Proliferation and Promotes Apoptosis by Targeting UHRF1 in Lung Cancer. Technology in Cancer Research & Treatment. 20. 2203783079–2203783079. 7 indexed citations
11.
Ma, Yu‐Shui, Xiaofeng Wang, Yunjie Zhang, et al.. (2020). Inhibition of USP14 Deubiquitinating Activity as a Potential Therapy for Tumors with p53 Deficiency. Molecular Therapy — Oncolytics. 16. 147–157. 26 indexed citations
12.
Ma, Yu‐Shui, Fei Yu, Xiaoming Zhong, et al.. (2018). miR-30 Family Reduction Maintains Self-Renewal and Promotes Tumorigenesis in NSCLC-Initiating Cells by Targeting Oncogene TM4SF1. Molecular Therapy. 26(12). 2751–2765. 35 indexed citations
13.
Ma, Yu‐Shui, Huiqiong Yang, Shaobo Xue, et al.. (2018). Reduced hsa-miR-124-3p levels are associated with the poor survival of patients with hepatocellular carcinoma. Molecular Biology Reports. 45(6). 2615–2623. 40 indexed citations
14.
Ma, Yu‐Shui, Zhongwei Lv, Fei Yu, et al.. (2018). MicroRNA-302a/d inhibits the self-renewal capability and cell cycle entry of liver cancer stem cells by targeting the E2F7/AKT axis. Journal of Experimental & Clinical Cancer Research. 37(1). 252–252. 64 indexed citations
15.
Ma, Yu‐Shui, Tao Huang, Xiaoming Zhong, et al.. (2018). Proteogenomic characterization and comprehensive integrative genomic analysis of human colorectal cancer liver metastasis. Molecular Cancer. 17(1). 139–139. 66 indexed citations
16.
Zhao, Bingkun, Shanshan Qin, Li Chai, et al.. (2018). Evaluation of astatine-211-labeled octreotide as a potential radiotherapeutic agent for NSCLC treatment. Bioorganic & Medicinal Chemistry. 26(5). 1086–1091. 18 indexed citations
17.
Xie, Ruting, Xianling Cong, Xiaoming Zhong, et al.. (2018). MicroRNA-33a downregulation is associated with tumorigenesis and poor prognosis in patients with hepatocellular carcinoma. Oncology Letters. 15(4). 4571–4577. 18 indexed citations
18.
Zhang, Yunjie, Yu‐Shui Ma, Qing Xia, et al.. (2018). MicroRNA‑mRNA integrated analysis based on a case of well‑differentiated thyroid cancer with both metastasis and metastatic recurrence. Oncology Reports. 40(6). 3803–3811. 9 indexed citations
19.
Luo, Ping, Gai‐Xia Lu, Linlin Fan, et al.. (2017). Dysregulation of TMPRSS3 and TNFRSF11B correlates with tumorigenesis and poor prognosis in patients with breast cancer. Oncology Reports. 37(4). 2057–2062. 19 indexed citations
20.
Hou, Likun, Yu‐Shui Ma, Yang Han, et al.. (2017). Association of microRNA-33a Molecular Signature with Non-Small Cell Lung Cancer Diagnosis and Prognosis after Chemotherapy. PLoS ONE. 12(1). e0170431–e0170431. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shi-Xun Lu Breakdown of academic impact, for papers by Mariangela Balistreri Breakdown of academic impact, for papers by Yanmei Cui Breakdown of academic impact, for papers by Jue‐Yu Zhou Breakdown of academic impact, for papers by Zetian Shen Breakdown of academic impact, for papers by Ai‐Yan Xing Breakdown of academic impact, for papers by Shican Yan Breakdown of academic impact, for papers by Weimin Mao Breakdown of academic impact, for papers by Maria Apicella Breakdown of academic impact, for papers by Daniel Kerr
Rankless by CCL
2026